|
|
|
|
|
|
|
|
BioFuture 2026 (October 27–28 in New York City) is two days of programming that tackles what biopharma is actually working through: funding gaps, policy shifts, AI convergence. 500+ global attendees tackle the industry's hardest questions and build the relationships that move their companies forward. More at https://biofuture.com.
|
|
|
|
|
|
|
Precision oncology only works when effective biomarker testing helps identify the right patients before launch, explains Boehringer Ingelheim’s Vicky Brown.
|
|
|
|
|
|
|
|
|
|
|
|
From Disconnected Data To AI-Ready Manufacturing
|
Disconnected manufacturing data limits quality and AI readiness. A connected IT/OT foundation helps teams reduce downtime, improve QC speed, and turn production data into trusted intelligence.
|
|
|
|
|
|
|
|
|
|
How To Accelerate Early-Phase Oncology Trial
|
Purpose-built early-phase oncology sites can enroll patients within 7–10 days post-activation while maintaining quality and diversity; academic centers often lag due to complexity and saturation.
|
|
|
|
|
| Connect With Life Science Leader: |
|
|
|
|